loading
Schlusskurs vom Vortag:
$1.19
Offen:
$1.22
24-Stunden-Volumen:
21,578
Relative Volume:
0.30
Marktkapitalisierung:
$7.08M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-13.32M
KGV:
-0.1993
EPS:
-6.02
Netto-Cashflow:
$-13.01M
1W Leistung:
-4.76%
1M Leistung:
-14.29%
6M Leistung:
-43.66%
1J Leistung:
-34.43%
1-Tages-Spanne:
Value
$1.19
$1.22
1-Wochen-Bereich:
Value
$1.16
$1.29
52-Wochen-Spanne:
Value
$1.145
$2.6702

Plus Therapeutics Inc Stock (PSTV) Company Profile

Name
Firmenname
Plus Therapeutics Inc
Name
Telefon
737.255.7194
Name
Adresse
4200 MARATHON BLVD., AUSTIN, TX
Name
Mitarbeiter
20
Name
Twitter
@plustxinc
Name
Nächster Verdiensttermin
2024-11-04
Name
Neueste SEC-Einreichungen
Name
PSTV's Discussions on Twitter

Vergleichen Sie PSTV mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
PSTV 1.2093 7.08M 0 -13.32M -13.01M -6.02
VRTX 449.84 115.43B 10.63B -479.80M -1.35B 13.33
REGN 744.58 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 591.18 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 245.91 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 107.39 24.89B 3.30B -501.07M 1.03B 11.54

Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2021-01-25 Eingeleitet Ladenburg Thalmann Buy
2020-10-16 Eingeleitet Maxim Group Buy

Plus Therapeutics Inc Aktie (PSTV) Neueste Nachrichten

pulisher
07:31 AM

Plus Therapeutics to Present Multi-Institutional Experience - GlobeNewswire

07:31 AM
pulisher
07:30 AM

Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases - Yahoo Canada Finance

07:30 AM
pulisher
Nov 19, 2024

HC Wainwright Reiterates Buy Rating for Plus Therapeutics (NASDAQ:PSTV) - Defense World

Nov 19, 2024
pulisher
Nov 19, 2024

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Short Interest Update - Defense World

Nov 19, 2024
pulisher
Nov 18, 2024

Jones Trading cuts PSTV stock target, maintains Buy rating on Q3 earnings - Investing.com

Nov 18, 2024
pulisher
Nov 18, 2024

Earnings call: Plus Therapeutics reports progress and financials for Q3 2024 - Investing.com

Nov 18, 2024
pulisher
Nov 17, 2024

Plus Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 17, 2024
pulisher
Nov 15, 2024

Plus: Q3 Earnings Snapshot - New Haven Register

Nov 15, 2024
pulisher
Nov 15, 2024

Plus Therapeutics Inc (PSTV) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... - Yahoo Finance

Nov 15, 2024
pulisher
Nov 14, 2024

Plus Therapeutics Advances Radiotherapeutics in Q3 2024 - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire

Nov 14, 2024
pulisher
Nov 14, 2024

PLUS THERAPEUTICS Inc (PSTV) Quarterly 10-Q Report - Quartzy

Nov 14, 2024
pulisher
Nov 11, 2024

Leptomeningeal Metastases Clinical Trials 2024: FDA - openPR

Nov 11, 2024
pulisher
Nov 09, 2024

Undercovered Dozen: Asbury Automotive, Globalstar, Northland Power, Aquestive Therapeutics - Seeking Alpha

Nov 09, 2024
pulisher
Nov 08, 2024

Sitravatinib Plus Nivo-Ipi Appears Safe, Active in ccRCC - Cancer Therapy Advisor

Nov 08, 2024
pulisher
Nov 07, 2024

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Nov 07, 2024
pulisher
Nov 06, 2024

Plus Therapeutics partners with SpectronRx for cancer therapy - Investing.com India

Nov 06, 2024
pulisher
Nov 06, 2024

Plus Therapeutics partners with SpectronRx for cancer therapy By Investing.com - Investing.com UK

Nov 06, 2024
pulisher
Nov 06, 2024

Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership - GlobeNewswire

Nov 06, 2024
pulisher
Nov 06, 2024

Plus Thera teams up with SpectronRx for radiotherapy production - The Pharma Letter

Nov 06, 2024
pulisher
Nov 05, 2024

Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024 - GlobeNewswire

Nov 05, 2024
pulisher
Nov 05, 2024

Plus Therapeutics (PSTV) Sets Q3 2024 Earnings Call for November 14 | PSTV Stock News - StockTitan

Nov 05, 2024
pulisher
Nov 01, 2024

Plus Therapeutics granted extension by Nasdaq - Investing.com

Nov 01, 2024
pulisher
Oct 29, 2024

Leptomeningeal Metastases Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca - The Globe and Mail

Oct 29, 2024
pulisher
Oct 29, 2024

Plus Therapeutics Showcases Leptomeningeal Metastases - GlobeNewswire

Oct 29, 2024
pulisher
Oct 27, 2024

Simulations Plus, Inc. (NASDAQ:SLP) Receives $56.00 Consensus Price Target from Analysts - Defense World

Oct 27, 2024
pulisher
Oct 24, 2024

Metastatic Colorectal Cancer Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Daiichi Sankyo Company, Mirati Therapeutics, Apollomics - Barchart

Oct 24, 2024
pulisher
Oct 21, 2024

Evaluating Immunotherapy as Systemic Therapy Plus RT in Early-Stage NSCLC - Cancer Network

Oct 21, 2024
pulisher
Oct 21, 2024

Colorectal Cancer Pipeline Overview 2024: FDA Approvals and Key Companies involved by DelveInsight | Novartis, Pharma Oncology, Purple Biotech Ltd, Plus Therapeutics, Processa Pharma - The Globe and Mail

Oct 21, 2024
pulisher
Oct 19, 2024

Curio Digital Therapeutics Applauded by Frost & Sullivan for Enhancing Women's Maternal Mental Healthcare with its MamaLift and MamaLift Plus Solutions - The Malaysian Reserve

Oct 19, 2024
pulisher
Oct 15, 2024

Prescription Digital Therapeutics for Mental Health: A New Era in Psychiatry - Psychiatry Advisor

Oct 15, 2024
pulisher
Oct 13, 2024

SalioGen Therapeutics hit by layoffs, as gene-editing biotechs continue to struggle - STAT

Oct 13, 2024
pulisher
Oct 06, 2024

Ultra-Hypofractionated Radiation May Mitigate Breast Cancer Recurrence - Cancer Network

Oct 06, 2024
pulisher
Oct 01, 2024

Plus Therapeutics reports progress in brain cancer trial - Investing.com

Oct 01, 2024
pulisher
Oct 01, 2024

Plus Therapeutics reports progress in brain cancer trial By Investing.com - Investing.com Canada

Oct 01, 2024
pulisher
Oct 01, 2024

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Oct 01, 2024
pulisher
Oct 01, 2024

Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting - ForexTV.com

Oct 01, 2024
pulisher
Oct 01, 2024

Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update - GlobeNewswire

Oct 01, 2024
pulisher
Oct 01, 2024

Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of ... - The Bakersfield Californian

Oct 01, 2024
pulisher
Sep 30, 2024

Dow Tumbles Over 200 Points; Carnival Posts Upbeat Earnings - Benzinga

Sep 30, 2024
pulisher
Sep 25, 2024

Celldex drug reduces chronic hive activity, but patient discontinuations raise questions - STAT

Sep 25, 2024
pulisher
Sep 24, 2024

Cipaglucosidase alfa plus miglustat: linking mechanism of action to clinical outcomes in late-onset Pompe disease - Frontiers

Sep 24, 2024
pulisher
Sep 23, 2024

Elevar Therapeutics Resubmits New Drug Application to FDA - GlobeNewswire

Sep 23, 2024
pulisher
Sep 23, 2024

Elevar Therapeutics Resubmits New Drug Application to FDA for Combination of Camrelizumab plus Rivoceranib as First-Line Treatment Option for Unresectable Hepatocellular Carcinoma Boosted by CARES-310 Leading Overall Survival Analysis - Yahoo Finance

Sep 23, 2024
pulisher
Sep 22, 2024

Bluejay Diagnostics (NASDAQ:BJDX) versus Plus Therapeutics (NASDAQ:PSTV) Head-To-Head Review - Defense World

Sep 22, 2024
pulisher
Sep 19, 2024

Plus Therapeutics to present at CNS Annual Meeting By Investing.com - Investing.com Canada

Sep 19, 2024
pulisher
Sep 19, 2024

From 'science fiction to reality': New George Church-founded biotech raises $75M for cell therapy platform - Fierce Biotech

Sep 19, 2024
pulisher
Sep 18, 2024

Plus Therapeutics to present at CNS Annual Meeting - Investing.com

Sep 18, 2024
pulisher
Sep 18, 2024

Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 - GlobeNewswire

Sep 18, 2024
pulisher
Sep 18, 2024

Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting - StockTitan

Sep 18, 2024

Finanzdaten der Plus Therapeutics Inc-Aktie (PSTV)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):